Home › Trials › NCT07587710
Clinical trial Recruiting at 2 sites Phase 1 Interventional Ages 18 to 80

Blood levels and tolerance of NNC0487-0111 in people with overweight/obesity and varying liver function

Official title: A Study Investigating the Pharmacokinetic Properties, Safety and Tolerability of NNC0487-0111 in Participants With Various Degrees of Hepatic Impairment and Participants With Normal Hepatic Function

Run by Novo Nordisk A/S · NCT07587710 · Data updated 2026-11-12

This study tests a new medicine (NNC0487-0111) to see if it is safe and how it behaves in people with overweight or obesity, with or without liver impairment.

More Obesity trials

Quick facts

PhasePhase 1
Study typeInterventional
Ages18 Years to 80 Years
SexAll
Enrollment35 (estimated)
SponsorNovo Nordisk A/S
Industry-sponsored
Locations2 sites (Bratislava and 1 other locations)
StatusRecruiting
StartedMay 13, 2026
Main results expectedDecember 1, 2027
Study endsDecember 1, 2027
Registry record updatedNovember 10, 2026
Trial IDNCT07587710 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Adults aged 18-80 with overweight or obesity, including individuals with stable hepatic impairment (Child-Pugh A, B, or C).

Probably not a fit

People without overweight/obesity or without liver impairment may not benefit from this study, and all candidates may not experience improvement in health outcomes.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This Phase 1 interventional trial examines NNC0487-0111 in adults with overweight or obesity, including those with stable liver impairment. The study aims to determine safety, tolerability, and pharmacokinetics across participants with normal and reduced liver function. Participants will receive the study drug and will be monitored for adverse effects and how the drug is processed in the body. The investigation is sponsored by Novo Nordisk and conducted at two sites in Slovakia.

Why it matters

Potential benefit: If successful, participants may experience safer dosing guidance and better understanding of how the drug behaves in different liver function states.

How similar studies have gone: Early-phase trials for similar therapies have shown that liver function can affect drug exposure, supporting the need for this investigation.

Who can join: the full rules

Show full inclusion / exclusion criteria 
Inclusion Criteria:

* Male or female (sex at birth).
* Age 18-80 years (both inclusive) at the time of signing informed consent.
* Participants with stable hepatic impairment classified as Child-Pugh grade A, B or C as assessed by the investigator. Stable hepatic impairment is defined as no clinically significant change in disease status, as judged by the investigator.

Exclusion Criteria:

* Known or suspected hypersensitivity to study intervention(s) or related products.
* Female who is pregnant, breast-feeding or intends to become pregnant or is of child-bearing potential and not using a highly effective contraceptive method.

Where it's running

  • Summit Clinical Research s.r.o.
    Bratislava, Slovakia     Recruiting
  • Summit Clinical Research s.r.o.
    Malacky, Slovakia     Recruiting

Study contacts

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
View on ClinicalTrials.gov ↗ Find more trials like this →
Browse more
Overweight 159Obesity 1426Novo Nordisk A/S 70
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.